ACH

$2.36

Market ClosedAs of Mar 17, 8:00 PM UTC

Accendra Health, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$2.36
Potential Upside
5%
Whystock Fair Value$2.48
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Distribution

Accendra Health, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States. It offers a range of products and services for in-home care and delivery for diabetes treatment; home respiratory therapy, includi...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$180.39M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.29
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-163.78%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.40

Recent News

Zacks
Mar 13, 2026

Is the Options Market Predicting a Spike in Accendra Health Stock?

Investors need to pay close attention to Accendra Health stock based on the movements in the options market lately.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Insider Monkey
Feb 24, 2026

Accendra Health (ACH) Reports 2025 Revenue of $2.8B and Shift Toward Core Home-Based Care

Accendra Health Inc. (NYSE:ACH) is one of the most undervalued penny stocks to buy right now. On February 19, Accendra Health reported full-year 2025 revenue of nearly $2.8 billion, which was a 3% year-over-year increase. Despite this growth, Q4 adjusted EBITDA fell to $90 million from $102.5 million in the prior year, bringing the annual […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Feb 20, 2026

Accendra Health Inc (ACH) Q4 2025 Earnings Call Highlights: Navigating Challenges and Strategic ...

Despite revenue growth and strategic divestitures, Accendra Health Inc (ACH) faces headwinds from payer loss and inflationary pressures while prioritizing debt reduction and technology investments.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Simply Wall St.
Feb 8, 2026

Henry Schein Leadership Exit Tests Distribution Strength And Competitive Position

Henry Schein's former president of U.S. Distribution has left the company to become Chief Commercial Officer at Owens & Minor. The executive move involves a senior leader with decades of experience overseeing Henry Schein's U.S. distribution operations. The change raises questions for investors about continuity in Henry Schein's core distribution business and competitive positioning in healthcare supply. For investors watching Henry Schein (NasdaqGS:HSIC), this leadership change comes with...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MT Newswires
Jan 20, 2026

Asian Equities Traded in the US as American Depositary Receipts Drop Sharply in Tuesday Trading

Asian equities traded in the US as American depositary receipts opened the shortened trading week sh

BEARISH
Negative press. News cycle fixated on risk factors or misses.